These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37203300)

  • 1. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study.
    Xiang Q; Wang Z; Mu G; Xie Q; Liu Z; Zhou S; Zhang H; Wang Z; Jiang J; Hu K; Zhang Y; Zhao Z; Yuan D; Guo L; Wu T; Zhang J; Wang N; Xiang J; Gu Z; Sun J; Cui Y
    Clin Transl Med; 2023 May; 13(5):e1263. PubMed ID: 37203300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study.
    Xiang Q; Xie Q; Liu Z; Mu G; Zhang H; Zhou S; Wang Z; Wang Z; Zhang Y; Zhao Z; Yuan D; Guo L; Wang N; Xiang J; Song H; Sun J; Jiang J; Cui Y
    Clin Transl Med; 2022 Dec; 12(12):e1104. PubMed ID: 36453946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban.
    Sakaguchi T; Osanai H; Murase Y; Ishii H; Nakashima Y; Asano H; Suzuki S; Takefuji M; Inden Y; Sakai K; Murohara T; Ajioka M
    J Cardiol; 2017 Sep; 70(3):244-249. PubMed ID: 28017463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
    Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus.
    Peacock WF; Tamayo S; Sicignano N; Hopf KP; Yuan Z; Patel M
    Am J Cardiol; 2017 Mar; 119(5):753-759. PubMed ID: 28081941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
    Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.
    Nakagawara J; Ikeda T; Ogawa S; Kitazono T; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Cardiol; 2019 Dec; 74(6):501-506. PubMed ID: 31371191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.
    Kirchhof P; Haas S; Amarenco P; Hess S; Lambelet M; van Eickels M; Turpie AGG; Camm AJ;
    J Am Heart Assoc; 2020 Mar; 9(5):e009530. PubMed ID: 32079476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection.
    Yu Y; Li H; Liu J; Liang Q; Xie J; Sun G
    Am J Cardiovasc Drugs; 2024 Jan; 24(1):129-139. PubMed ID: 38142441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
    Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
    Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
    [No Abstract]   [Full Text] [Related]  

  • 18. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
    J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
    Ueno EI; Fujibayashi K; Sawaguchi J; Yasuda Y; Takano S; Fujioka N; Kawai Y; Fujita H; Tanaka Y; Kajinami K
    J Thromb Thrombolysis; 2020 Aug; 50(2):371-379. PubMed ID: 32166540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.